Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

γ-Aminobutyric Acid Enhancement of CL 218,872 Affinity and Evidence of Benzodiazepine Receptor Heterogeneity

JOHN W. REGAN, WILLIAM R. ROESKE, JEFFREY B. MALICK, SUSAN H. YAMAMURA and HENRY I. YAMAMURA
Molecular Pharmacology November 1981, 20 (3) 477-483;
JOHN W. REGAN
Departments of Pharmacology, Psychiatry, and Internal Medicine, University of Arizona Health Sciences Center, Tucson, Arizona 85724, and Biomedical Research Department, ICI Americas Inc., Wilmington, Delaware 19897
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
WILLIAM R. ROESKE
Departments of Pharmacology, Psychiatry, and Internal Medicine, University of Arizona Health Sciences Center, Tucson, Arizona 85724, and Biomedical Research Department, ICI Americas Inc., Wilmington, Delaware 19897
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JEFFREY B. MALICK
Departments of Pharmacology, Psychiatry, and Internal Medicine, University of Arizona Health Sciences Center, Tucson, Arizona 85724, and Biomedical Research Department, ICI Americas Inc., Wilmington, Delaware 19897
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SUSAN H. YAMAMURA
Departments of Pharmacology, Psychiatry, and Internal Medicine, University of Arizona Health Sciences Center, Tucson, Arizona 85724, and Biomedical Research Department, ICI Americas Inc., Wilmington, Delaware 19897
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HENRY I. YAMAMURA
Departments of Pharmacology, Psychiatry, and Internal Medicine, University of Arizona Health Sciences Center, Tucson, Arizona 85724, and Biomedical Research Department, ICI Americas Inc., Wilmington, Delaware 19897
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The inhibition of [3H]flunitrazepam binding by a novel anxiolytic agent [CL 218,872; 3-methyl-6-[3-trifluoromethyl)phenyl]-l,2,4-triazolo-[4,3-b]pyridazine] was studied in membranes prepared from bovine retina and rat cerebral cortex, cerebellum, and kidney. The order of potency for the inhibition of [3H]fluintrazepam binding by CL 218,872 in these tissues was cerebellum > retina ≅ cerebral cortex » kidney. The slope factors (Hill coefficients) for CL 218,872 inhibition of [3H]flunitrazepam were approximately 1.0 for kidney, 0.9 for cerebellum, and 0.7 for cerebral cortex and retina. In thoroughly washed membrane preparations from all of the central tissues, Ki values were significantly decreased an average of 60% in the presence of 100 µM γ-aminobutyric acid (GABA) (p < 0.01). With kidney membranes there was no apparent affect of GABA on the Ki of CL 218,872. (+)-Bicuculline (100 µM) could antagonize the effect of GABA on membranes from central tissues. Nonlinear least-squares regression analyses were used to reanalyze these data in terms of receptor models describing the interaction of a ligand with either one or two classes of independent binding sites. A two-site regression model resulted in a highly significant improvement in the fit of data obtained from retina, cerebral cortex, and cerebellum (p < 0.01), but not with data from kidney (p > 0.05). GABA was found to enhance the affinity of CL 218,872 for both of the sites without changing the proportion of sites. The results of these studies show that GABA enhances the affinity of CL 218,872 for the central benzodiazepine receptor(s) and that the inhibition of [3H]flunitrazepam binding by CL 218,872 in bovine retina, rat cerebellum, and cerebral cortex may be explained by interactions with two classes of independent binding sites.

ACKNOWLEDGMENTS The authors thank William H. Ruth for his technical assistance and Isabelle Preiss for her secretarial assistance.

  • Copyright © 1981 by The American Society for Pharmacology and Experimental Therapeutics

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology
Vol. 20, Issue 3
1 Nov 1981
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
γ-Aminobutyric Acid Enhancement of CL 218,872 Affinity and Evidence of Benzodiazepine Receptor Heterogeneity
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

γ-Aminobutyric Acid Enhancement of CL 218,872 Affinity and Evidence of Benzodiazepine Receptor Heterogeneity

JOHN W. REGAN, WILLIAM R. ROESKE, JEFFREY B. MALICK, SUSAN H. YAMAMURA and HENRY I. YAMAMURA
Molecular Pharmacology November 1, 1981, 20 (3) 477-483;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

γ-Aminobutyric Acid Enhancement of CL 218,872 Affinity and Evidence of Benzodiazepine Receptor Heterogeneity

JOHN W. REGAN, WILLIAM R. ROESKE, JEFFREY B. MALICK, SUSAN H. YAMAMURA and HENRY I. YAMAMURA
Molecular Pharmacology November 1, 1981, 20 (3) 477-483;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • The binding site for KCI807 in the androgen receptor
  • Fatty acid amide hydrolase in cisplatin nephrotoxicity
  • eCB Signaling System in hiPSC-Derived Neuronal Cultures
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics